Answers are grounded in this paper and cite their sources.
Background Acute kidney injury (AKI) is a common and serious complication after cardiac surgery, with limited preventive strategies. Glutamate supplementation may reduce AKI indirectly by enhancing recovery of post-ischaemic myocardial metabolism and function; however, its metabolic effects appear attenuated in diabetic hearts. We investigated the association between glutamate infusion and postoperative AKI in patients without diabetes mellitus undergoing coronary artery bypass grafting (CABG), according to preoperative risk and kidney function. Methods This post hoc analysis pooled data from two randomised, double-blind, placebo-controlled GLUTAMICS trials. Patients without diabetes mellitus undergoing CABG with or without concomitant valve surgery were allocated to i.v. 0.125 M L-glutamic acid or saline. AKI was defined as a postoperative increase in plasma creatinine ≥50% from baseline (RIFLE risk stage or higher) and analysed according to European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) quartiles and estimated creatinine clearance. Results Among 791 patients, 391 received glutamate and 400 received placebo. In the combined two highest EuroSCORE II quartiles, AKI incidence was lower with glutamate (8.0% vs 16.8%; relative risk [RR] 0.47; 95% confidence interval [CI] 0.27–0.84; P =0.011). Among patients with an estimated creatinine clearance of ≥50 ml min −1 , AKI occurred in 2.7% vs 9.6% (RR 0.28; 95% CI 0.14–0.58; P <0.001). No benefit was observed with severe preoperative kidney dysfunction (estimated creatinine clearance <50 ml min −1 ). Significant interactions were observed between glutamate allocation and preoperative risk ( P =0.025) and severe preoperative kidney dysfunction ( P =0.027). Conclusions Glutamate infusion was associated with a lower incidence of AKI in higher-risk patients without diabetes mellitus, particularly those without severe preoperative kidney dysfunction. These exploratory findings require prospective confirmation. Trial registration number ClinicalTrials.gov (NCT00489827 and NCT02592824).
No takes yet. Share an insight, caveat, or question.
Svedjeholm et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: